Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects

Skin Therapy Letter-Family Practice Edition

Seena Monjazeb¹  Brent Kelly¹  Janice Wilson¹ 

[1] School of Medicine, Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA 

关键词: epidermal growth factor receptor;    EGFR;    epidermal growth factor receptor inhibitor;    EGFR inhibitor;    erlotinib;    cetuximab;    targeted therapy;    antineoplastic therapy;    medication toxicity;    cutaneous side effects;    cutaneous adverse events;    acneiform eruption;    paronychia;   

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as “targeted therapy,” which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients’ quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs. 

【 授权许可】

CC BY